Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options
for moderate‐to‐severe disease are limited. Ustekinumab is an IL‐12/IL‐23p40 antagonist …

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that
affects children and adults. Until recently, the only Food and Drug Administration–approved …

Background Moderate-to-severe atopic dermatitis (AD) is increasingly recognized as a
systemic disease, largely due to proteomic blood studies. There are growing efforts to …

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated
with a high skin‐related health burden, typically starting in childhood and often persisting …

Current atopic dermatitis (AD) models link epidermal abnormalities in lesional skin to
cytokine activation. However, there is evolving evidence of systemic immune activation and …

Background Molecular studies in atopic dermatitis (AD) are largely restricted to patients with
moderate-to-severe disease. Objective Our aim was to evaluate skin and blood …

Atopic dermatitis (AD) is one of the most prevalent inflammatory disease among non-fatal
skin diseases, affecting up to one fifth of the population in developed countries. AD is …

Objective To provide an overview of studies contributing to the understanding of
immunologic, microbial, and epithelial interactions in atopic dermatitis. Data Sources …

Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by
recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life …

Atopic dermatitis (AD) is a heterogeneous disease with unique clinical manifestations across
age groups and race/ethnicities. Characteristic molecular mechanisms, known as …